Loading…
Loading…
ORGS does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ORGS and 80,000+ other tickers.
See exactly how ORGS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ORGS and 80,000+ other tickers.
Orgenesis Inc. is a global biotechnology firm dedicated to the field of cell and gene therapies. The company has engineered an innovative Point of Care (POCare) platform. This system incorporates a portfolio of licensed POCare therapeutics, which are manufactured and prepared using automated, self-contained POCare technology within a cooperative network. Orgenesis primarily concentrates on autologous therapies, developing customized processes and systems for each treatment. These utilize a closed, automated processing methodology, validated for safe and compliant production directly at the…
Plano, Texas--(Newsfile Corp. - March 26, 2026) - Okogen Inc., a biotechnology company developing antiviral therapeutics, today announced the acquisition of the global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc. (OTC: ORGS), strengthening the company's lead ophthalmic program and establishing a foundation for expansion into additional antiviral indications. The acquisition expands the company's development pipeline beyond ocular infections into a set of focused therapeutic areas: eyecare, systemic infectious disease, dermatology and medical countermeasures for high-consequence pathogens such as filoviruses, which form the core pillars of Okogen's Ranpirnase Platform.
Orgenesis (NASDAQ: ORGS - Get Free Report) and UCB (OTCMKTS:UCBJF - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability. Insider and Institutional Ownership 22.6% of Orgenesis shares are held
Orgenesis Inc. (NASDAQ: ORGS - Get Free Report) shares rose 300% during mid-day trading on Thursday. The stock traded as high as $0.60 and last traded at $0.60. Approximately 100 shares traded hands during trading, a decline of 84% from the average daily volume of 636 shares. The stock had previously closed at $0.15. Orgenesis
Volatility and Risk eFFECTOR Therapeutics has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 3.44, suggesting that its stock price is 244% more volatile than the S&P 500. Earnings and Valuation This table compares eFFECTOR Therapeutics and Orgenesis"s gross revenue,
Volatility and Risk Orgenesis has a beta of 3.16, suggesting that its stock price is 216% more volatile than the S&P 500. Comparatively, Statera Biopharma has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500. Insider and Institutional Ownership 22.6% of Orgenesis shares are held by institutional